Syndax Pharmaceuticals, Inc. SNDX R2K

Healthcare · Biotechnology · United States

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Market & Price

Market Cap

$1.74B

Current Price

$19.59

High / Low (52W)

$25.15 / $8.73

Beta

0.41

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$0.74

Price to Book

26.51

P/S

7.99

EV/EBITDA

-7.69

Dividend Yield

Profitability & Returns

ROCE

-61.44%

ROE

ROA

-25.12%

Profit Margin

Op Margin

-52.73%

EPS (Latest Qtr)

$-0.48

EPS (TTM)

$-2.79

Balance Sheet & Liquidity

Debt/Equity

8.30

Quick Ratio

4.90

Current Ratio

5.47

Debt

$345.36M

Total Assets

$529.71M

Current Assets

$528.08M

Working Capital

$407.96M

Ownership

Promoter Holding

1.72%

Chg in Prom Hold

FII / Inst Holding

116.13%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.72B

Total Revenue (TTM)

$217.17M

EBITDA

$-223.77M

Free Cash Flow

$-186.01M

Operating Cash Flow

$-278.16M

Shares Outstanding

88.61M

Gross Margin

-23.17%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

-30.37%

Revenue (YoY)

223.60%

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -30.4% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SNDX Syndax Pharmaceuticals, Inc. R2K	19.59	-	$1.74B	-	-61.44%	-	-	-30.37%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	305.00K	305.00K	305.00K	1.19M	379.00K	379.00K	379.00K	380.00K	379.00K	379.00K	379.00K	380.00K	379.00K	379.00K	379.00K	380.00K	379.00K	379.00K	12.38M	-	-	-	-	0	0	0	3.50M	12.50M	20.04M	37.96M	45.87M	68.73M	64.86M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	885.00K	1.28M	2.10M	2.71M	2.63M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.16M	36.68M	43.77M	66.02M	62.23M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	102.91M	106.03M	101.20M	128.57M	96.43M
Operating Income	-5.54M	-5.86M	-4.68M	-8.75M	-8.63M	-15.24M	-11.14M	-13.18M	-13.84M	-15.45M	-19.49M	-19.75M	-18.95M	-17.84M	-19.33M	-14.81M	-15.37M	-13.15M	-14.21M	-15.10M	-16.61M	-19.85M	-19.86M	-27.16M	-22.33M	-20.03M	-36.86M	-37.72M	-35.14M	-46.02M	-49.68M	-56.35M	-79.51M	-74.22M	-89.58M	-83.76M	-69.35M	-57.43M	-62.55M	-34.20M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-76.80M	-63.99M	-52.43M	-58.42M	-30.82M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.05M	7.86M	8.28M	9.59M	11.85M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-84.85M	-71.85M	-60.72M	-68.01M	-42.67M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-6.21M	-7.73M	-5.26M	-10.33M	-8.36M	-14.97M	-10.81M	-12.97M	-13.64M	-15.09M	-19.10M	-19.40M	-18.39M	-17.34M	-18.84M	-14.30M	-14.92M	-12.83M	-14.00M	-15.24M	-17.06M	-20.44M	-20.42M	-27.72M	-22.91M	-20.64M	-37.17M	-37.57M	-35.40M	-41.13M	-44.62M	-51.15M	-72.40M	-68.06M	-84.13M	-84.85M	-71.85M	-60.72M	-68.01M	-42.67M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.44	-0.40	-0.63	-0.62	-0.58	-0.59	-0.64	-0.73	-0.85	-0.80	-0.98	-0.98	-0.83	-0.70	-0.78	-0.48
R&D Expense	2.27M	2.97M	2.59M	4.79M	6.13M	12.27M	8.47M	9.55M	9.86M	12.19M	16.60M	15.34M	14.85M	14.10M	15.82M	11.28M	12.29M	9.92M	9.50M	9.56M	10.94M	14.41M	15.52M	21.87M	16.87M	25.61M	30.02M	29.73M	26.90M	34.05M	34.76M	39.09M	56.49M	48.66M	70.97M	61.64M	62.23M	56.28M	-	58.84M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	1.22M	2.11M	1.52M	1.52M	1.52M	-	0	0	23.68M	172.35M
Cost of Revenue	-	-	-	-	-	-	-	-	0	0	826.00K	6.97M
Gross Profit	-	-	-	-	-	-	-	-	0	0	22.85M	165.38M
Operating Expenses	-	-	-	-	-	-	-	-	151.76M	229.95M	362.53M	438.47M
Operating Income	-21.33M	-20.51M	-43.77M	-61.95M	-75.88M	-57.54M	-71.42M	-	-151.76M	-229.95M	-339.67M	-273.08M
EBITDA	-	-	-	-	-	-	-	-	-146.17M	-209.14M	-313.82M	-251.63M
Interest Expense	-	-	-	-	-	-	-	-	3.14M	208.00K	4.93M	33.78M
Pretax Income	-	-	-	-	-	-	-	-	-149.34M	-209.36M	-318.76M	-285.42M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-19.83M	-24.12M	-44.47M	-60.80M	-73.96M	-56.05M	-73.16M	-	-149.34M	-209.36M	-318.76M	-285.42M
Diluted EPS	-	-	-	-	-	-1.84	-1.87	-	-2.46	-2.98	-3.72	-3.29
R&D Expense	10.18M	9.55M	31.66M	48.20M	60.11M	42.99M	50.44M	88.25M	118.50M	163.03M	241.65M	258.78M

Compounded Sales Growth

5 Years:	-
1 Year:	223.60%

Compounded Profit Growth

5 Years:	-30.37%
1 Year:	-

Stock Price Performance

1 Year:	+85.86%
6 Months:	+0.72%
3 Months:	-9.77%
1 Month:	-5.04%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	89.90M	109.01M	137.19M	83.94M	63.52M	300.61M	-	497.24M	612.88M	724.82M	529.71M
Current Assets	-	-	-	-	-	-	-	-	-	489.79M	580.88M	603.06M	528.08M
Cash & Equivalents	10.10M	10.01M	23.18M	23.84M	35.17M	33.77M	24.61M	115.24M	-	74.36M	295.39M	154.08M	134.93M
Inventory	-	-	-	-	-	-	-	-	-	-	0	366.00K	32.75M
Receivables	-	-	-	-	-	-	-	-	-	3.47M	0	7.60M	38.00M
Total Liabilities	-	-	23.20M	24.87M	32.87M	30.89M	31.93M	48.42M	-	29.79M	58.68M	436.69M	465.08M
Current Liabilities	-	-	4.85M	10.37M	15.80M	16.11M	18.37M	18.87M	-	29.07M	58.10M	103.55M	120.12M
Long Term Debt	-	-	-	-	-	-	-	-	19.89M	-	-	331.56M	343.91M
Total Debt	-	-	-	-	-	-	-	-	-	1.16M	1.64M	345.74M	345.43M
Total Equity	-128.47M	-152.57M	-252.41M	84.14M	104.32M	53.05M	31.60M	252.19M	-	467.45M	554.20M	288.12M	64.63M
Shares Outstanding	-	-	-	-	-	-	-	-	-	68.11M	84.83M	85.69M	87.41M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-35.16M	-47.37M	-68.53M	-50.61M	-71.26M	-	-133.68M	-160.60M	-274.90M	-322.98M
Investing Cash Flow	-	-	-18.28M	-17.07M	51.40M	12.78M	-142.53M	-	-186.19M	117.61M	-219.78M	290.04M
Financing Cash Flow	-	-	54.20M	75.72M	15.73M	28.57M	304.42M	-	172.25M	264.13M	353.37M	13.68M
Capital Expenditure	-4.00K	-49.00K	-261.00K	-84.00K	-187.00K	-	-0	-129.00K	-	-	-	-187.00K
Free Cash Flow	-	-	-35.42M	-47.45M	-68.72M	-	-71.26M	-	-133.68M	-160.60M	-274.90M	-323.17M
Net Change in Cash	-	-	-	-	-	-	-	-	-147.61M	221.14M	-141.31M	-19.27M

Ratios (Annual)

Figures in %.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	96.5%	96.0%
Operating Margin %	-	-	-3,587.4%	-2,939.0%	-5,001.7%	-3,792.9%	-4,708.2%	-	-	-	-1,434.4%	-158.4%
Net Margin %	-	-	-3,645.2%	-2,884.3%	-4,875.5%	-3,694.6%	-4,822.5%	-	-	-	-1,346.1%	-165.6%
ROE %	13.0%	9.6%	-52.9%	-58.3%	-139.4%	-177.4%	-29.0%	-	-31.9%	-37.8%	-110.6%	-441.6%
ROCE %	-	-24.1%	-44.4%	-51.0%	-111.9%	-127.4%	-25.4%	-	-32.4%	-41.4%	-54.7%	-66.7%

Shareholding Pattern

Insiders

1.72%

Institutions

116.13%

Public Float

118.17%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.32%	8.25M	$161.70M
2	Kynam Capital Management, LP	9.09%	8.05M	$157.72M
3	Goldman Sachs Group Inc	5.64%	5.00M	$97.89M
4	State Street Corporation	5.00%	4.43M	$86.79M
5	Bank of America Corporation	4.80%	4.25M	$83.25M
6	Vanguard Capital Management LLC	4.31%	3.82M	$74.88M
7	Deerfield Management Company, L.P	4.27%	3.78M	$74.05M
8	Eversept Partners, LP	3.26%	2.89M	$56.53M
9	Kingdon Capital Management LLC	2.82%	2.50M	$48.98M
10	Hood River Capital Management LLC	2.66%	2.35M	$46.12M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SNDX

No recent headlines available.

SNDX · Healthcare